[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 12, 1966

Propranolol Hydrochloride in the Treatment of Angina Pectoris

Author Affiliations

From the Department of Medicine, Duke University School of Medicine, Cardiovascular Disease Service, Duke University Medical Center, Durham, NC. Dr. Ginn is a fellow in cardiovascular disease.

JAMA. 1966;198(11):1214-1216. doi:10.1001/jama.1966.03110240122045

PROPRANOLOL hydrochloride (Inderal), a new beta adrenergic receptor blocking agent, apparently possessing a potency ten to 20 times that of its predecessor, pronetalol,1 yet lacking its tumor producing qualities in mice,2 recently has received clinical trial in the treatment of angina pectoris.

Strivastava and associates3 using propranolol, 20 mg three times daily in a double-blind study of 20 patients exhibiting angina pectoris, found no statistically significant difference in frequency of angina pectoris or nitroglycerin consumption. However, Keelan4 in a similar study of 19 patients but employing larger doses of propranolol, 30 mg three times daily, observed significant reduction in frequency of angina pectoris and in number of nitroglycerin tablets used. Gillam and Prichard,5 utilizing maximum tolerated doses of propranolol, 30 mg to a ceiling of 100 mg four times daily, recorded significant improvement in all 14 patients studied.

The present paper reports the results of